{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:05:24Z","timestamp":1792757124136,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jacc.2024.08.023","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T03:30:21Z","timestamp":1724988621000},"page":"1603-1614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart\u00a0Failure With Preserved Ejection Fraction"],"prefix":"10.1016","volume":"84","author":[{"given":"Subodh","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalane W.","family":"Kitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Jon","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"R\u00f6nnb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-0723","authenticated-orcid":false,"given":"Bela","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"O\u2019Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.08.023_bib1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jacc.2022.08.718","article-title":"Atrial fibrillation and dapagliflozin efficacy in patients with preserved or mildly reduced ejection fraction","volume":"80","author":"Butt","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.08.023_bib2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ejhf.2861","article-title":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation","volume":"25","author":"Filippatos","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.08.023_bib3","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2017.09.002","article-title":"Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise","volume":"70","author":"Lavie","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.08.023_bib4","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2024.08.023_bib5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCULATIONAHA.117.031394","article-title":"Response by Obokata and Borlaug to letters regarding article, \"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction.\"","volume":"137","author":"Obokata","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.08.023_bib6","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.08.023_bib7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.08.023_bib8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.08.023_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamacardio.2020.0136","article-title":"Therapeutic targeting of left atrial myopathy in atrial fibrillation and heart failure with preserved ejection fraction","volume":"5","author":"Patel","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2024.08.023_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jchf.2017.05.001","article-title":"Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"5","author":"Sartipy","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2024.08.023_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchf.2019.09.002","article-title":"HFpEF is the substrate for stroke in obesity and diabetes independent of atrial fibrillation","volume":"8","author":"Packer","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2024.08.023_bib12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ejhf.3221","article-title":"Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: principal findings and meta-analysis with the DELIVER trial","volume":"26","author":"Sattar","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.08.023_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jchf.2016.10.005","article-title":"Atrial fibrillation in heart failure with preserved ejection fraction: association with exercise capacity, left\u00a0ventricular filling pressures, natriuretic peptides, and left atrial volume","volume":"5","author":"Lam","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2024.08.023_bib14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","article-title":"Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study","volume":"128","author":"Zakeri","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.08.023_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.08.023_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF Program","volume":"84","author":"Petrie","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.08.023_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program","volume":"84","author":"Schou","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"35","key":"10.1016\/j.jacc.2024.08.023_bib18","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.08.023_bib19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide in heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of\u00a0the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.08.023_bib20","article-title":"Impact of obesity on atrial fibrillation pathogenesis and treatment options","volume":"13","author":"Sha","year":"2024","journal-title":"J\u00a0Am Heart Assoc"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724081956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724081956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T12:15:59Z","timestamp":1738412159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724081956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":20,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0735109724081956"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.08.023","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart\u00a0Failure With Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}